Loading organizations...
BillionToOne: Develops precision genetic tests for prenatal screening and oncology liquid biopsy using proprietary QCTs and smNGS.
BillionToOne has raised $464.5M across 7 funding rounds.
Key people at BillionToOne.
BillionToOne was founded in 2016 by Oguzhan Atay (Founder) and David Tsao (Founder/CTO).
BillionToOne has raised $464.5M in total across 7 funding rounds.
Based in Menlo Park, California, BillionToOne is a precision molecular diagnostics company that develops high-resolution genetic testing platforms for prenatal screening and oncology liquid biopsies. The publicly traded enterprise utilizes its proprietary quantitative counting templates and single-molecule sequencing to detect and measure disease-causing cell-free DNA fragments at the single base-pair level. Operating with a workforce of over 500 employees, the company has administered more than one million of its UNITY fetal risk tests to date and achieved a valuation exceeding $1 billion following a $130 million Series D funding round. BillionToOne has raised over $350 million in total venture capital from institutional investors including Adams Street Partners and Hummingbird Ventures, while providing clinical diagnostic services to healthcare providers, patients, and Medicare. The diagnostics organization was founded in 2016 by Oguzhan Atay and David Tsao.
Key people at BillionToOne.
BillionToOne was founded in 2016 by Oguzhan Atay (Founder) and David Tsao (Founder/CTO).
BillionToOne has raised $464.5M in total across 7 funding rounds.
BillionToOne's investors include Premji Invest, Anterra Capital, Hummingbird Ventures, Battery Ventures, Lightspeed Venture Partners, Neotribe Ventures, WestWave Capital, Kira Makagon, Adams Street Partners, Broom Ventures, HOF Capital, Rebel Fund.
BillionToOne is a precision molecular diagnostics company specializing in advanced genetic testing platforms that detect and measure disease at the single base-pair level. Their proprietary technology, Quantitative Counting Templates (QCTs™), enables highly sensitive detection of tiny and sparse DNA fragments, which has revolutionized prenatal screening and liquid biopsy for cancer. Their flagship product, UNITY Fetal Risk™ Screen, is a non-invasive prenatal test (NIPT) that uniquely assesses fetal risk for both aneuploidies and recessive genetic conditions from maternal blood without requiring paternal samples. BillionToOne serves clinicians and patients seeking accurate, early disease detection, addressing critical gaps in prenatal and oncology diagnostics. The company has demonstrated rapid growth, with over 1 million UNITY tests completed and expanding into oncology liquid biopsy markets, supported by substantial funding rounds and regulatory approvals.
Founded in 2016 by PhD scientists Oguzhan Atay and David Tsao, BillionToOne emerged from a vision to improve healthcare through better disease detection using molecular counting technology. Early traction came from a National Institutes of Health grant in 2018 for the first single-gene NIPT clinical study with Baylor University, validating their approach. The company started in a shared lab space and quickly scaled to its own CLIA-certified lab, securing $15 million in Series A funding by 2019. Over time, BillionToOne expanded its product portfolio and clinical validation, culminating in a $130 million Series D funding round in 2024 and a public IPO filing in 2025, reflecting its evolution from a startup to a leading player in precision diagnostics.
BillionToOne rides the wave of precision medicine and non-invasive diagnostics, leveraging advances in genomics and molecular counting to transform prenatal care and oncology. The timing is critical as demand grows for early, accurate, and less invasive disease detection methods. Market forces such as increasing healthcare personalization, regulatory support for innovative diagnostics, and rising patient awareness favor BillionToOne’s expansion. Their technology not only improves clinical outcomes but also influences the broader ecosystem by setting new standards for molecular diagnostic sensitivity and specificity, encouraging innovation across genomics and liquid biopsy sectors.
BillionToOne is positioned to continue its trajectory as a leader in precision diagnostics, expanding its prenatal and oncology testing offerings while exploring new applications of its QCT technology. Trends shaping their journey include increasing adoption of non-invasive tests, integration of AI in genomics, and growing emphasis on personalized medicine. Their influence is likely to deepen as they drive standards for molecular counting accuracy and broaden access to advanced diagnostics through Medicare and other payers. Looking ahead, BillionToOne’s platform could redefine disease detection paradigms, making precise, personalized care accessible on a global scale.
BillionToOne has raised $464.5M across 7 funding rounds. Most recently, it raised $130.0M Series D in June 2024.
